Orchid Pharma Q4 FY26 Results: Standalone Profit ₹3060 Cr, Consolidated Profit ₹2378 Cr
Orchid Pharma reported Q4 FY26 standalone profit of ₹3060.37 lakh and consolidated profit of ₹2378.51 lakh. For FY26, standalone profit was ₹4520.79 lakh and consolidated profit was ₹2120.83 lakh. The company appointed an internal auditor for FY27 and completed acquisitions in Germany. Amalgamation with Dhanuka Laboratories is pending NCLT order.
The announcement includes quarterly and annual financial results, which are material. The completion of acquisitions and the pending amalgamation are significant corporate actions that could impact the company's future operations and structure.
The financial results show a mixed performance with a significant standalone profit but a lower consolidated profit compared to the previous year. While there are positive developments like acquisitions and auditor appointments, the modified opinion on consolidated results and pending amalgamation introduce some caution.
Orchid Pharma Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported a standalone profit of ₹3,060.37 lakh for the quarter and a consolidated profit of ₹2,378.51 lakh for the same period. For the full financial year ended March 31, 2026, the standalone profit stood at ₹4,520.79 lakh, while the consolidated profit was ₹2,120.83 lakh.
The Board of Directors also approved the appointment of the Internal Auditor for the Financial Year 2026-27. The statutory auditors issued an unmodified opinion on the standalone financial results and a modified opinion on the consolidated financial results. The company has also successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS, consolidating global ownership of Enmetazobactam (EXBLIFEP/Orblicef).
Furthermore, the company is pursuing amalgamation with its Holding Company, Dhanuka Laboratories Limited, with the NCLT having reserved its order. The company also reported on the utilization of funds raised through Qualified Institutional Placement (QIP), with a balance of ₹6,198 lakh kept in fixed deposits as of March 31, 2026.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.